Posted by Michael Wonder on 28 Jun 2026
Skyrizi (risankizumab-rzaa) now FDA approved for paediatric use in psoriatic disease
26 June 2026 - AbbVie today announced the US FDA has approved Skyrizi (risankizumab-rzaa) for the treatment of children six years of age and older with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy, or active psoriatic arthritis.
A new 55 mg pre-filled syringe has also been approved to support weight-based dosing for patients weighing less than 40 kg, while the currently available 150 mg pre-filled syringe and pre-filled pen are approved for patients weighing 40 kg or greater.
